$15.24
2.83%
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US05337M1045
Symbol
AVDL

Avadel Pharmaceuticals PLC Sponsored ADR Target price 2025 - Analyst rating & recommendation

Avadel Pharmaceuticals PLC Sponsored ADR Classifications & Recommendation:

Buy
93%
Hold
7%

Avadel Pharmaceuticals PLC Sponsored ADR Price Target

Target Price $16.83
Price $15.24
Potential
Number of Estimates 10
10 Analysts have issued a price target Avadel Pharmaceuticals PLC Sponsored ADR 2026 . The average Avadel Pharmaceuticals PLC Sponsored ADR target price is $16.83. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 13 Analysts recommend Avadel Pharmaceuticals PLC Sponsored ADR to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Avadel Pharmaceuticals PLC Sponsored ADR stock has an average upside potential 2026 of . Most analysts recommend the Avadel Pharmaceuticals PLC Sponsored ADR stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 169.12 265.15
504.86% 56.78%
EBITDA Margin -23.49% 13.96%
95.17% 159.44%
Net Margin -28.87% 8.35%
94.96% 128.92%

10 Analysts have issued a sales forecast Avadel Pharmaceuticals PLC Sponsored ADR 2025 . The average Avadel Pharmaceuticals PLC Sponsored ADR sales estimate is

$265m
Unlock
. This is
19.93% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$275m 24.20%
Unlock
, the lowest is
$252m 14.16%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $169m 504.86%
2025
$265m 56.78%
Unlock
2026
$346m 30.46%
Unlock
2027
$412m 19.15%
Unlock
2028
$457m 10.97%
Unlock
2029
$491m 7.26%
Unlock

5 Analysts have issued an Avadel Pharmaceuticals PLC Sponsored ADR EBITDA forecast 2025. The average Avadel Pharmaceuticals PLC Sponsored ADR EBITDA estimate is

$37.0m
Unlock
. This is
531.84% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$38.5m 557.59%
Unlock
, the lowest is
$35.2m 500.38%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-39.7m 70.81%
2025
$37.0m 193.22%
Unlock
2026
$132m 257.72%
Unlock
2027
$209m 58.01%
Unlock
2028
$141m 32.46%
Unlock
2029
$164m 16.16%
Unlock

EBITDA Margin

2024 -23.49% 95.17%
2025
13.96% 159.44%
Unlock
2026
38.29% 174.28%
Unlock
2027
50.78% 32.62%
Unlock
2028
30.91% 39.13%
Unlock
2029
33.47% 8.28%
Unlock

11 Avadel Pharmaceuticals PLC Sponsored ADR Analysts have issued a net profit forecast 2025. The average Avadel Pharmaceuticals PLC Sponsored ADR net profit estimate is

$22.1m
Unlock
. This is
858.22% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$39.6m 1,457.19%
Unlock
, the lowest is
$9.5m 424.66%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-48.8m 69.53%
2025
$22.1m 145.34%
Unlock
2026
$76.2m 244.08%
Unlock
2027
$135m 77.09%
Unlock

Net Margin

2024 -28.87% 94.96%
2025
8.35% 128.92%
Unlock
2026
22.02% 163.71%
Unlock
2027
32.73% 48.64%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.51 0.23
74.50% 145.10%
P/E 66.62
EV/Sales 5.27

11 Analysts have issued a Avadel Pharmaceuticals PLC Sponsored ADR forecast for earnings per share. The average Avadel Pharmaceuticals PLC Sponsored ADR EPS is

$0.23
Unlock
. This is
866.67% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.41 1,466.67%
Unlock
, the lowest is
$0.10 433.33%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.51 74.50%
2025
$0.23 145.10%
Unlock
2026
$0.79 243.48%
Unlock
2027
$1.39 75.95%
Unlock

P/E ratio

Current -508.00 3,405.65%
2025
66.62 113.11%
Unlock
2026
19.36 70.94%
Unlock
2027
10.93 43.54%
Unlock

Based on analysts' sales estimates for 2025, the Avadel Pharmaceuticals PLC Sponsored ADR stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.32 58.91%
2025
5.27 16.56%
Unlock
2026
4.04 23.35%
Unlock
2027
3.39 16.07%
Unlock
2028
3.06 9.89%
Unlock
2029
2.85 6.77%
Unlock

P/S ratio

Current 6.69 58.50%
2025
5.58 16.62%
Unlock
2026
4.28 23.35%
Unlock
2027
3.59 16.07%
Unlock
2028
3.24 9.89%
Unlock
2029
3.02 6.77%
Unlock

Current Avadel Pharmaceuticals PLC Sponsored ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
UBS
Locked
Locked
Locked Aug 21 2025
HC Wainwright & Co.
Locked
Locked
Locked Aug 08 2025
Needham
Locked
Locked
Locked May 08 2025
Needham
Locked
Locked
Locked Apr 09 2025
Needham
Locked
Locked
Locked Mar 04 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 04 2025
Needham
Locked
Locked
Locked Mar 03 2025
Analyst Rating Date
Locked
UBS:
Locked
Locked
Aug 21 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 08 2025
Locked
Needham:
Locked
Locked
May 08 2025
Locked
Needham:
Locked
Locked
Apr 09 2025
Locked
Needham:
Locked
Locked
Mar 04 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 04 2025
Locked
Needham:
Locked
Locked
Mar 03 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today